Document Detail

Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases.
Jump to Full Text
MedLine Citation:
PMID:  19997642     Owner:  NLM     Status:  MEDLINE    
Inflammation affects the formation and the progression of various vitreoretinal diseases. We performed a comprehensive analysis of inflammatory immune mediators in the vitreous fluids from total of 345 patients with diabetic macular edema (DME, n = 92), proliferative diabetic retinopathy (PDR, n = 147), branch retinal vein occlusion (BRVO, n = 30), central retinal vein occlusion (CRVO, n = 13) and rhegmatogenous retinal detachment (RRD, n = 63). As a control, we selected a total of 83 patients with either idiopathic macular hole (MH) or idiopathic epiretinal membrane (ERM) that were free of major pathogenic intraocular changes, such as ischemic retina and proliferative membranes. The concentrations of 20 soluble factors (nine cytokines, six chemokines, and five growth factors) were measured simultaneously by multiplex bead analysis system. Out of 20 soluble factors, three factors: interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1) were significantly elevated in all groups of vitreoretinal diseases (DME, PDR, BRVO, CRVO, and RRD) compared with control group. According to the correlation analysis in the individual patient's level, these three factors that were simultaneously increased, did not show any independent upregulation in all the examined diseases. Vascular endothelial growth factor (VEGF) was significantly elevated in patients with PDR and CRVO. In PDR patients, the elevation of VEGF was significantly correlated with the three factors: IL-6, IL-8, and MCP-1, while no significant correlation was observed in CRVO patients. In conclusion, multiplex bead system enabled a comprehensive soluble factor analysis in vitreous fluid derived from variety of patients. Major three factors: IL-6, IL-8, and MCP-1 were strongly correlated with each other indicating a common pathway involved in inflammation process in vitreoretinal diseases.
Takeru Yoshimura; Koh-hei Sonoda; Mika Sugahara; Yasutaka Mochizuki; Hiroshi Enaida; Yuji Oshima; Akifumi Ueno; Yasuaki Hata; Hiroki Yoshida; Tatsuro Ishibashi
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-12-04
Journal Detail:
Title:  PloS one     Volume:  4     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-09     Completed Date:  2010-03-17     Revised Date:  2010-09-28    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e8158     Citation Subset:  IM    
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cytokines / blood
Diabetic Retinopathy / blood,  immunology,  pathology
Inflammation Mediators / blood,  metabolism*
Middle Aged
Models, Biological
Retinal Diseases / blood,  immunology*,  pathology*
Retinal Vein Occlusion / blood,  immunology,  pathology
Vascular Endothelial Growth Factor A / blood
Vitreoretinopathy, Proliferative / blood,  immunology,  pathology
Vitreous Body / immunology*,  pathology*
Reg. No./Substance:
0/Cytokines; 0/Inflammation Mediators; 0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Yoshimura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received Day: 25 Month: 6 Year: 2009
Accepted Day: 11 Month: 11 Year: 2009
collection publication date: Year: 2009
Electronic publication date: Day: 4 Month: 12 Year: 2009
Volume: 4 Issue: 12
E-location ID: e8158
ID: 2780733
PubMed Id: 19997642
Publisher Id: 09-PONE-RA-11504R1
DOI: 10.1371/journal.pone.0008158

Comprehensive Analysis of Inflammatory Immune Mediators in Vitreoretinal Diseases Alternate Title:Vitreoretinal Immunity
Takeru Yoshimura1
Koh-Hei Sonoda1*
Mika Sugahara1
Yasutaka Mochizuki1
Hiroshi Enaida1
Yuji Oshima1
Akifumi Ueno1
Yasuaki Hata1
Hiroki Yoshida2
Tatsuro Ishibashi1
Rafael Lindenedit1 Role: Editor
1Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Nabeshima, Saga, Japan
Universidade Federal do Rio de Janeiro (UFRJ), Brazil
Correspondence: * E-mail:
Contributed by footnote: Conceived and designed the experiments: TY KHS. Performed the experiments: TY MS. Analyzed the data: TY KHS MS. Contributed reagents/materials/analysis tools: KHS YM HE YO AU YH HY TI. Wrote the paper: TY KHS. Assembled the figures: TY KHS. Interpretation of the results: TY KHS MS YO TI. Wrote the first draft of the manuscript: TY. Collection of vitreous samples: KHS YM HE YO AU YH. Supervision of the laboratory experiments: HY.


Vitreoretinal diseases, such as diabetic retinopathy (DR), retinal vein occlusion (RVO), and retinal detachment (RD) have a poor visual prognosis. Although these diseases have variety of etiology, their pathogenic retinal changes (including angiogenesis and fibrosis) cause local inflammation. In fact, infiltration of leukocytes into the choroid, retina, and vitreous is observed in various vitreoretinal disorders, including PDR [1], proliferative vitreoretinopathy (PVR) [2], as well as in obvious inflammatory ocular diseases such as endophthalmitis and uveitis. Even though such leukocyte infiltration may be only a secondary event, it damages retinal tissues.

During inflammation a variety of soluble factors are secreted into the vitreous cavity (posterior chamber of the eye) and their concentrations may reflect visual prognosis. Cytokines, which usually serve as signals between neighboring cells, are involved in essentially every important biological process, including cell proliferation, inflammation, immunity, migration, fibrosis, tissue repair, and angiogenesis [3], [4]. Chemokines are multifunctional mediators that can direct the recruitment of leukocytes to sites of inflammation, promote the process, enhance immune responses, and promote stem cell survival, development, and homeostasis [5]. Recently, it has been demonstrated that chemokines play a pivotal role in mediating angiogenesis and fibrosis as well [6], [7].

DR is one of the most severe complication of diabetes mellitus and a leading cause of blindness. DR can further be divided into non-proliferative diabetic retinopathy (NPDR) and PDR. NPDR causes central vision loss when it induces DME. PDR is the most advanced stage of DR, which is characterized by retinal neovasculization. The pathology of PDR includes vitreous hemorrhage, formation of fibrous peri-retinal tissue comprising neovascular blood vessels, tractional retinal detachment and total vision loss as the final stage. Various mechanisms play a role in the pathogenesis of DR, including the disruption of blood-retinal barrier, alterations to capillary vessel walls, synthesis of growth factors and nitric oxide, disruption of connective tissue by matrix metalloproteinases, and activation of various immune mechanisms.

RVO is another common retinal vascular disorder and a common cause of visual impairment. Between the two types of RVO, BRVO is more common than CRVO. The pathogenesis of CRVO is multifactorial while BRVO is believed to be driven by a combination of three primary mechanisms: compression of the vein at the arteriovenous crossing, degenerative changes of the vessel wall, and abnormal hematological factors [8].

RRD is defined as the separation of the neurosensory retina from subjacent retinal pigment epithelium (RPE) caused by penetration of fluids into the subretinal space via one or more full-thickness retinal breaks. Initial detachment may be local, but without rapid treatment the entire retina may detach, which may lead to vision loss and blindness. Lewandowska-Furmanik et al. suggested the involvement of the immune system in pathogenesis of RRD following the detection of some cytokine concentrations in subretinal fluid of 36 RRD patients [9].

Aiello et al. reported VEGF was detected from ocular fluid with diabetic retinopathy and other retinal disorders [10]: there are other reports measuring multiple soluble factors in samples from different vitreoretinal disorders using conventional enzyme-linked immunosorbent assay (ELISA) [11]-[16]. However, the examination of complex patterns of these factors in human vitreoretinal diseases has been limited by the small number of vitreous samples available from each patient. Recently, a particle-based flow cytometric analysis method has been established to improve the conventional method and overcome many of these limitations [17]. Two recent studies demonstrated the analysis of vitreous inflammatory mediators by multiplex bead analysis in 58 patients with several vitreoretinal disorders and 32 patients with diabetic patients [18], [19]. Djoba Siawaya and colleagues [20] compared between the multiplex assays based on Luminex technology and established ELISA technique. Their conclusion was that currently the most appropriate use for the Luminex technology is as a screening tool.

In this study we report the use of Luminex technique for analysis of complex network of immune mediators in vitreous humor and the relations between them; we examined a profile of immune mediators in 345 eyes from patients undergoing vitrectomy. Moreover, the correlations between several immune mediators related to different vitreoretinal diseases were determined. Finding patterns in expression of inflammatory cytokines specific to a particular disease can substantially contribute to the understanding of the basic mechanism of this disease and consequently to the development of a targeted therapy.

Detection of Soluble Factors in Vitreous Fluids from Patients

The bibliography of enrolled patients was shown in Table 1. The investigated inflammatory mediators were categorized into three groups: (1) nine cytokines: IL-1?, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?) (Table 2); (2) six chemokines: IL-8, eotaxin, MCP-1/CCL2, macrophage inflammatory protein-1? (MIP-1?), MIP-1?, and regulated on activation, normal T cell expressed and secreted (RANTES)/CCL5 (Table 3); and (3) five growth factors: epidermal growth factor (EGF), VEGF, basic FGF, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Table 4). We found that four out of twenty soluble factors: IL-6, IL-8, MCP-1, and VEGF were predominantly detected in vitreous fluids from patients (Table 2-pone-0008158-t0034). In addition, MIP-1?, G-CSF, and GM-CSF were detected in limited number of patients. For instance, we found one CRVO patient with extremely high concentration of these four cytokines (IL-6: 11103 pg/ml, IL-8: 6821 pg/ml, MCP-1: 15403 pg/ml, VEGF: 11737 pg/ml) that showed extra high concentrations of G-CSF (467.6 pg/ml) and GM-CSF (1036 pg/ml).

The concentrations of IL-1?, IL-2, IL-4, IL-5, IL-10, IL-17, IFN-?, TNF-?, eotaxin, MIP-1?, RANTES, EGF and bFGF were under the detection level in all the examined samples (the minimal detectable concentration is listed in Table 2?pone-0008158-t0034). Technical issues were excluded as control recombinant proteins were detected (data not shown). Moreover, concentrations of soluble factors (IFN-?, TNF-?, and IL-2) in aqueous humor from acute uveitis patients (some samples were actually measured on the same plate in this study series) were detected [21], in accordance with previous findings [22]. In addition extremely high concentrations of IL-10 were detected in vitreous fluids from intraocular malignant lymphoma patients in this system (data not shown), in support with previous findings [23].

IL-6, IL-8 and MCP-1 Were Increased in All Examined Diseases, but VEGF Was Increased in PDR and CRVO Patients Only

Since the four factors (IL-6, IL-8, MCP-1 and VEGF) could be detected in the majority of the patients, we decided to further study these factors. In Figure 1, every individual dot represents a measured concentration which is plotted in log scale (y axis) and bars represent the mean value of each group. Compared with control subjects (either ERM or MH), the concentrations of IL-6 (Figure 1A), IL-8 (Figure 1B), and MCP-1 (Figure 1C) were significantly higher in patients with DME, PDR, BRVO, CRVO, and RRD. VEGF levels were significantly higher in samples from patients with either PDR or CRVO than in control(Figure 1D), but not in samples from DME nor BRVO despite the same category of disease used (DR and RVO, respectively). RD patients did not show any elevated levels of VEGF.

The concentrations of all four factors, IL-6, IL-8, MCP-1 and VEGF, were significantly high within the same disease category, where in PDR the level was higher than DME, and in CRVO these factors level were higher than in BRVO (Figure 1A?D).

IL-6, IL-8 and MCP-1 Are Mutually Increased in All Analyzed Vitreoretinal Diseases

Since the three factors: IL-6, IL-8 and MCP-1 were commonly upregulated in all the examined five diseases (DME, PDR, BRVO, CRVO, and RRD), a Spearman's correlation analysis was performed between the three factors. In each disease, we analyzed total of three combinations (two factors out of three), represented in dots, and calculated p- and r-values which indicate the accuracy of the correlation. An example is the correlation shown in DME data where the dots are placed along with the median line, p-values are less than 0.05, and r-values are high in all three combinations (IL-6/IL-8, IL-6/MCP-1 and IL-8/MCP-1) (Figure 2). This setting means that the three factors are correlated with each other in DME patients. The results of p-values and r-values are shown in Figure 3 (upper three lines). All three combinations of IL-6/IL-8, IL-6/MCP-1 and IL-8/MCP-1 in the studied groups showed significant correlations (p<0.05) except from IL-8/MCP-1 in CRVO (Figure 3, upper three lines).

VEGF Independently Contribute to the Pathogenic Process of PDR and CRVO

Since VEGF was significantly increased in PDR and CRVO patients (Figure 1), the correlation between VEGF and the three factors: IL-6, IL-8, and MCP-1 in PDR and CRVO were investigated. Figure 3 shows the result of six combinations including VEGF in PDR (Figure 4A) and CRVO (Figure 4B). The p-values and r-values are summarized in Figure 3 (lower three lines). In PDR patients, the elevation of VEGF was significantly correlated with the other three factors, while no significant correlation was observed in CRVO patients (Figure 3, lower three lines). Unlike the three factors: IL-6, IL-8 and MCP-1, VEGF was not a common factor, but may independently play a role in the pathologic process in PDR and CRVO.

Serum IL-6 and VEGF Concentrations Are Not Significantly Related with Vitreous Concentrations

Because vitreoretinal diseases examined in this study develop neovasculization in the eye, it is likely to expect that mediators in the circulation are easily and passively enter the vitreous. Therefore, we decided to measure the proteins in serum in PDR and CRVO groups as neovascularized eye diseases. Based on our findings, we measured IL-6, as a representative inflammatory marker, and VEGF concentrations in serum from control patients and patients with highly angiogenic diseases using standard ELISA technique. All serum samples we could have and vitreous samples which correspond to each patient were statistically analyzed (control: n?=?53, PDR: n?=?66, CRVO: n?=?8; Table 5 and Figure 5). Even in the reduced numbers, we confirmed vitreous IL-6/VEGF concentrations were significantly increased in PDR/CRVO patients than control. However, serum IL-6/VEGF concentrations were not increased in PDR/CRVO patients (Figure 5). The data clearly indicate that vitreous soluble factors are mainly from ocular tissues.


Inflammatory processes have been considered to be critical in vitreoretinal diseases [24]-[26]. The concentrations of inflammatory soluble factors might not necessarily reflect a pathogenic process, especially the microenvironments inside the retina. However, secreted factors in the vitreous cavity appear to be associated with pathological processes. Analyzing these factors can provide new insights relating to the biological mechanism of the disease and to the design of a therapeutic strategy: in fact, there are some reports suggesting intravitreal triamcinolone acetonide as a drug with an anti-inflammatory property [27]?[29]. Many studies describing the analysis of soluble factor profiles in vitreous fluids in a particular disease have been performed on limited numbers of patients [10]?[16]. We herein collected 345 samples from five different diseases and performed comprehensive analysis of 20 factors for the first time.

One of our most important finding is that the major three factors: IL-6, IL-8, and MCP-1 were commonly upregulated in all the examined diseases (Figure 1) and were correlated with each other without any independent change (Figure 3). The p-value of IL-8/MCP-1 in CRVO which was ?not significant?, (P?=?0.0899), but this may be due to the small number of samples (n?=?13) used. In general, the three factors (IL-6, IL-8, and MCP-1) were correlated with each other and increased synchronizing. This high correlation between the three factors indicates a common pathway is involved in the formation various vitreoretinal disorders (Figure 3, 6); IL-6 is a multifunctional cytokine that may indirectly cause an increase of vascular permeability by inducing the expression of VEGF [30] or alternatively may directly increase endothelial cell permeability [31]. IL-8 is produced by endothelial and glial cells in retinas with ischemic angiogenesis [32]. MCP-1 recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection [33], [34], and its upregulation may stimulate the infiltration of inflammatory cells into eyes with vitreoretinal disorders.

IL-6, IL-8 and MCP-1 have been independently reported to be regulated by nuclear factor-kappa B (NF-kB) [32], [35]-[39]. NF-kB is found in almost all cell types and is involved in cellular response to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, and bacterial or viral antigens, in addition to its central role in immune response [40]. On the other hand, VEGF is upregulated by hypoxia through hypoxia-inducible factor 1 alpha (HIF-1?) [41], which is another transcriptional factor that regulates genes which response to hypoxia [42]. As proposed in our study, VEGF may act in an independent pathway to promote the pathogenesis of all the analyzed vitreoretinal diseases, although additional studies are required to completely solve this mechanism. The difference in activation level of a transcription factor may determine the severity of ischemic, angiogenic, and inflammatory changes in ocular milieu.

Banerjee et al. [18] have reported that IL-6, IL-8 and MCP-1 were detected in vitreous fluids from patients with PDR, PVR, idiopathic choroidal neovascular membrane, chronic uveitis, and lens-induced uveitis (LIU). Furthermore, they reported that a LIU patient who went through a complicated phacoemulsification cataract surgery, had the most active disease with higher concentrations of IL-6 and IL-8 than in chronic uveitis or PDR. Combined with our results, the data indicate that the major three factors (IL-6, IL-8 and MCP-1) are critical in multiple vitreoretinal disorders including uveitis. In their report, however, except of LIU, the number of samples in each individual disease were less than ten, which significantly limited the performance of comprehensive analysis between several soluble factors.

Because DR (DME and PDR) and RVO (BRVO and CRVO) are characterized with ischemic retinal angiogenesis, it is reasonable that VEGF participate in their pathogenesis. Interestingly, the patients with PDR/CRVO showed increase of VEGF, but not DME/BRVO which had a significant increase of IL-6, IL-8, and MCP-1 (Figure 1). Nevertheless we do not suggest that VEGF has no contribution in DME/BRVO since the local levels of VEGF in the ocular tissues other than the vitreous may still be elevated. In fact, there are many reports about VEGF as a main exacerbating factor in DME [43], [44].

Another important point concerning DR/RVO, is that VEGF significantly correlated with the major three factors in PDR but not in CRVO. The reason for this may be an insufficient reliability of the correlation analysis due to the small number of samples from CRVO patients. However, in contrast to PDR, all p-values (VEGF/IL-6, VEGF/IL-8, VEGF/MCP-1) in CRVO were more than 0.5 which indicates no correlation (Figure 3 lower three lines, 4B). The lack of correlation may be a result of extremely high concentrations of VEGF in 3 out of 13 patients (more than 1?103 pg/ml) with no consistent high concentrations of the other three factors (IL-6, IL-8, and MCP-1). VEGF is produced from various types of retinal cells including retinal pigment epithelial cells, pericytes, endothelial cells, Muller cells, and astrocytes [45], [46]. Both ishemia and inflammation can initiate VEGF production.VEGF production can be induced by other factors and at the same time initiate a cascade of other factors. Our hypothesis is that IL-6, IL-8, and MCP-1 in the vitreous cavity promote vascular permeability that causes DME. Retinal ischemia leads to an excessive production of VEGF that in turn causes further progression of DME to PDR. On the other hand, a substantial amount of VEGF can be initially produced by the sudden profound retinal ischemia, which in turn induces the major three factors afterward (Figure 6).

Although RRD causes severe visual impairment, it does not induce inner retinal ischemia, which makes RRD a distinct disease from the other examined vitreoretinal diseases. It should be noted that the major three factors were increased unrelated with VEGF in RRD patients (Figure 1). Up to this point there have been reports on significantly high levels of MCP-1 in the vitreous of PVR (a major complications of RD surgery) patients compared to samples from patients with a macular hole or idiopathic premacular fibrosis [14], [47]?[49]. Nakazawa et al. [50] demonstrated that MCP-1 plays a critical role in mediating RD-induced photoreceptor apoptosis. Chong et al. [51] showed that IL-6 is a photoreceptor neuroprotectant in experimental model of RD. It is possible that factors induced by retinal detachment may have an additional function other than inflammation. Additional studies will be required to elucidate this point.

In conclusion, multiplex bead analysis enables a comprehensive analysis of several soluble factors in samples from patients with vitreoretinal disorders, using a small volume of vitreous fluid. The three factors: IL-6, IL-8, and MCP-1 were found to be commonly upregulated and contribute to the formation of various vitreoretinal diseases. VEGF may serve as an additional exacerbating factor in the progression of PDR, and an independent exacerbating factor in CRVO. Moreover, IL-6 and MCP-1 were prominently significant factors in the pathogenesis of RRD patients. Developing a Luminex base technique for the identification of immune mediator profiles in the vitreous opens up new possibilities of characterizing vitreoretinal diseases and designing therapies based on these unique correlations.

Materials and Methods
Study Population

Consecutive 339 patients underwent a pars plana vitrectomy (PPV) at Kyushu University Medical Center (Fukuoka, Japan). Only patients recruited from September 2005 to February 2007 were enrolled in this prospective study. Patients profile is shown in Table 1. DME was defined as DR with swelling of the retina caused by leaky vessels which can be detected by either ophthalmoscope/optical coherence tomography (OCT). PDR was defined as DR with obvious neovasculization with or without proliferative tissue. Macular edema complicated by BRVO or CRVO was considered as the decisive indication for PPV. As a control, we selected total 81 patients with either MH or ERM that were free of major pathogenic intraocular changes.

Vitreous Fluid and Serum Preparation

Under either general or topical anesthesia, undiluted vitreous fluid (200?900 ?l) was first collected by 3-port pars plana vitrectomy using a 20- or 23-gauge vitreous cutter with a 5 mL-syringe, followed by irrigation from infusion port. Samples were immediately placed in sterile 1.5 ml polypropylene tubes on ice and stored at ?70?C until used. Samples with obvious bleeding were excluded.

Serum samples were also obtained from patients. The samples were aliquoted and stored at ?70?C until use. However, not all of them were stored in a well condition. We thus need to reduce the numbers (control: n?=?83?53, PDR: n?=?147?66, CRVO: n?=?13?8), but we could measure the serum concentration of IL-6 and VEGF by standard ELISA technique. For comparison between serum and vitreous, vitreous IL-6/VEGF concentrations of corresponding individuals were extracted from previous measurement (shown in Figure 1), and then reorganized as Figure 5 and Table 5.

The research followed the tenets of the Declaration of Helsinki and the internal Ethics Committees of Kyushu University which approved all the protocols. Written informed consent was obtained from all enrolled patients.

Protein Analysis and Antibodies

To minimize interfering of fibers and gels in the samples, vitreous samples were diluted 1?10 in PBS. The concentration of cytokines, chemokines, and growth factors in vitreous specimens were measured using a microbead-based ELISA system [17]. Briefly, in this technique, microbeads with defined spectral properties are conjugated to protein-specific antibodies and added along with samples (samples include protein standards in a known concentration, control samples, and test samples) into wells of a filter-bottom microplate. This mixure is incubaed for 2 hrs to allow antibody and protein binding. After washing the beads, protein-specific biotinylated detector antibodies are added and incubated with the beads for 1 hr. Then after removal of excess biotinylated antibodies, streptavidin conjugated to a fluorescent protein: R-Phycoerythrin (Streptavidin-RPE), is added and incubated for 30 min. After washing of unbound Streptavidin-RPE, the beads are analyzed with the Luminex? 100 (Luminex, Austin, TX, USA). By monitoring the spectral properties of the beads and the amount of associated R-Phycoerythrin (RPE) fluorescence, the concentration of one or more proteins can be determined. The following antibodies were used: Human Cytokine Ten-Plex Antibody Bead Kit, Cat. No. LHC0001, Human IL-17 Antibody Bead Kit, Cat. No. LHC0171, Human Chemokine Five-Plex Antibody Bead Kit, Cat. No. LHC0005, Human Growth Factor Four-Plex Antibody Bead Kit, Cat. No. LHC0004; BioSource International, Camarillo USA). Serum samples were diluted 1?5 in PBS, then IL-6 and VEGF concentrations were measured by ELISA development kits (Human IL-6 DuoSet and Human VEGF Duoset, R&D systems, Minneapolis, MN) according to the manufacturer's directions.

Statistical Analysis

All analyses were performed with GraphPad Prism 4.0c (GraphPad Software Inc., San Diego, CA). A non-parametric Mann-Whitney U-test and Kruskal-Wallis test for non-normal distribution were used to analyze immune mediators and patient age variance, respectively. Correlation studies were performed by Spearman's non-parametric test. P-values less than 0.05 were considered as significantly different.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants from the Ministry of Education, Science, Sports and Culture, Japan (B2 No. 14770962: K-H. Sonoda, B2 No. 13470369: T. Ishibashi) ( The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We thank Dr. Robert J. D'Amato (Children's Hospital Boston, Harvard Medical School) for his critical reading and editing of the manuscript, and Dr. Ofra Benny for her editorial assistance. We also thank Ms. Michiyo Takahara and Dr. Yoshiyuki Miyazaki for their excellent technical support throughout all experiments and Dr. Hiroki Sanui for his financial support.

1. Canton A,Martinez-Caceres EM,Hernandez C,Espejo C,Garcia-Arumi J,et al. Year: 2004CD4-CD8 and CD28 expression in T cells infiltrating the vitreous fluid in patients with proliferative diabetic retinopathy: a flow cytometric analysis.Arch Ophthalmol12274374915136323
2. Charteris DG,Hiscott P,Grierson I,Lightman SL. Year: 1992Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes.Ophthalmology99136413671407970
3. Oppenheim JJ. Year: 2001Cytokines: past, present, and future.Int J Hematol743811530802
4. Vilcek J,Feldmann M. Year: 2004Historical review: Cytokines as therapeutics and targets of therapeutics.Trends Pharmacol Sci2520120915063084
5. Struyf S,Proost P,Van Damme J. Year: 2003Regulation of the immune response by the interaction of chemokines and proteases.Adv Immunol8114414711052
6. Strieter RM,Gomperts BN,Keane MP. Year: 2007The role of CXC chemokines in pulmonary fibrosis.J Clin Invest11754955617332882
7. Keeley EC,Mehrad B,Strieter RM. Year: 2008Chemokines as mediators of neovascularization.Arterioscler Thromb Vasc Biol281928193618757292
8. Rehak J,Rehak M. Year: 2008Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.Curr Eye Res3311113118293182
9. Lewandowska-Furmanik M,Pozarowska D,Pozarowski P,Matysik A. Year: 2002TH1/TH2 balance in the subretinal fluid of patients with rhegmatogenous retinal detachment.Med Sci Monit8CR52652812118203
10. Aiello LP,Avery RL,Arrigg PG,Keyt BA,Jampel HD,et al. Year: 1994Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.N Engl J Med331148014877526212
11. Abu el Asrar AM,Maimone D,Morse PH,Gregory S,Reder AT. Year: 1992Cytokines in the vitreous of patients with proliferative diabetic retinopathy.Am J Ophthalmol1147317361463043
12. de Boer JH,Hack CE,Verhoeven AJ,Baarsma GS,de Jong PT,et al. Year: 1993Chemoattractant and neutrophil degranulation activities related to interleukin-8 in vitreous fluid in uveitis and vitreoretinal disorders.Invest Ophthalmol Vis Sci34337633858225872
13. Elner SG,Elner VM,Jaffe GJ,Stuart A,Kunkel SL,et al. Year: 1995Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.Curr Eye Res14104510538585935
14. Capeans C,De Rojas MV,Lojo S,Salorio MS. Year: 1998C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy.Retina185465509869464
15. Pe'er J,Folberg R,Itin A,Gnessin H,Hemo I,et al. Year: 1998Vascular endothelial growth factor upregulation in human central retinal vein occlusion.Ophthalmology1054124169499769
16. Yuuki T,Kanda T,Kimura Y,Kotajima N,Tamura J,et al. Year: 2001Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy.J Diabetes Complications1525725911522500
17. Vignali DA. Year: 2000Multiplexed particle-based flow cytometric assays.J Immunol Methods24324325510986418
18. Banerjee S,Savant V,Scott RA,Curnow SJ,Wallace GR,et al. Year: 2007Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders.Invest Ophthalmol Vis Sci482203220717460280
19. Maier R,Weger M,Haller-Schober EM,El-Shabrawi Y,Wedrich A,et al. Year: 2008Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients.Mol Vis1463764318385799
20. Djoba Siawaya JF,Roberts T,Babb C,Black G,Golakai HJ,et al. Year: 2008An evaluation of commercial fluorescent bead-based luminex cytokine assays.PLoS ONE3e253518596971
21. Yoshimura T,Sonoda KH,Ohguro N,Ohsugi Y,Ishibashi T,et al. Year: 2009Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.Rheumatology (Oxford)4834735419164426
22. Takase H,Futagami Y,Yoshida T,Kamoi K,Sugita S,et al. Year: 2006Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis.Invest Ophthalmol Vis Sci471557156116565392
23. Chan CC,Buggage RR,Nussenblatt RB. Year: 2002Intraocular lymphoma.Curr Opin Ophthalmol1341141812441846
24. Joussen AM,Poulaki V,Le ML,Koizumi K,Esser C,et al. Year: 2004A central role for inflammation in the pathogenesis of diabetic retinopathy.Faseb J181450145215231732
25. Kastelan S,Zjacic-Rotkvic V,Kastelan Z. Year: 2007Could diabetic retinopathy be an autoimmune disease?Med Hypotheses681016101817125935
26. Adamis AP,Berman AJ. Year: 2008Immunological mechanisms in the pathogenesis of diabetic retinopathy.Semin Immunopathol30658418340447
27. Park SP,Ahn JK. Year: 2008Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion.Clin Experiment Ophthalmol3683183519278477
28. Arimura N,Otsuka H,Yamakiri K,Sonoda Y,Nakao S,et al. Year: 2009Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.Ophthalmology11692192619410951
29. Yilmaz T,Weaver CD,Gallagher MJ,Cordero-Coma M,Cervantes-Castaneda RA,et al. Year: 2009Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review.Ophthalmology116902911; quiz 912?90319410949
30. Cohen T,Nahari D,Cerem LW,Neufeld G,Levi BZ. Year: 1996Interleukin 6 induces the expression of vascular endothelial growth factor.J Biol Chem2717367418557680
31. Maruo N,Morita I,Shirao M,Murota S. Year: 1992IL-6 increases endothelial permeability in vitro.Endocrinology1317107141639018
32. Yoshida A,Yoshida S,Khalil AK,Ishibashi T,Inomata H. Year: 1998Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization.Invest Ophthalmol Vis Sci39109711069620068
33. Carr MW,Roth SJ,Luther E,Rose SS,Springer TA. Year: 1994Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.Proc Natl Acad Sci U S A91365236568170963
34. Xu LL,Warren MK,Rose WL,Gong W,Wang JM. Year: 1996Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro.J Leukoc Biol603653718830793
35. Matsusaka T,Fujikawa K,Nishio Y,Mukaida N,Matsushima K,et al. Year: 1993Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8.Proc Natl Acad Sci U S A9010193101978234276
36. Stein B,Baldwin AS Jr. Year: 1993Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B.Mol Cell Biol13719171988413306
37. Roebuck KA,Carpenter LR,Lakshminarayanan V,Page SM,Moy JN,et al. Year: 1999Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB.J Leukoc Biol6529129810080530
38. Goebeler M,Gillitzer R,Kilian K,Utzel K,Brocker EB,et al. Year: 2001Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells.Blood97465511133741
39. Li Q,Verma IM. Year: 2002NF-kappaB regulation in the immune system.Nat Rev Immunol272573412360211
40. Perkins ND. Year: 2007Integrating cell-signalling pathways with NF-kappaB and IKK function.Nat Rev Mol Cell Biol8496217183360
41. Forsythe JA,Jiang BH,Iyer NV,Agani F,Leung SW,et al. Year: 1996Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.Mol Cell Biol16460446138756616
42. Pages G,Pouyssegur J. Year: 2005Transcriptional regulation of the Vascular Endothelial Growth Factor gene?a concert of activating factors.Cardiovasc Res6556457315664382
43. Nguyen QD,Tatlipinar S,Shah SM,Haller JA,Quinlan E,et al. Year: 2006Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.Am J Ophthalmol14296196917046701
44. Funatsu H,Noma H,Mimura T,Eguchi S,Hori S. Year: 2009Association of vitreous inflammatory factors with diabetic macular edema.Ophthalmology116737919118698
45. Aiello LP,Northrup JM,Keyt BA,Takagi H,Iwamoto MA. Year: 1995Hypoxic regulation of vascular endothelial growth factor in retinal cells.Arch Ophthalmol113153815447487623
46. Lutty GA,McLeod DS,Merges C,Diggs A,Plouet J. Year: 1996Localization of vascular endothelial growth factor in human retina and choroid.Arch Ophthalmol1149719778694733
47. Charteris DG. Year: 1995Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.Br J Ophthalmol799539607488586
48. Abu el-Asrar AM,Van Damme J,Put W,Veckeneer M,Dralands L,et al. Year: 1997Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders.Am J Ophthalmol1235996069152065
49. Mitamura Y,Takeuchi S,Yamamoto S,Yamamoto T,Tsukahara I,et al. Year: 2002Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy.Jpn J Ophthalmol4621822112062231
50. Nakazawa T,Hisatomi T,Nakazawa C,Noda K,Maruyama K,et al. Year: 2007Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis.Proc Natl Acad Sci U S A1042425243017284607
51. Chong DY,Boehlke CS,Zheng QD,Zhang L,Han Y,et al. Year: 2008Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment.Invest Ophthalmol Vis Sci493193320018378582


[Figure ID: pone-0008158-g001]
doi: 10.1371/journal.pone.0008158.g001.
Figure 1  Detection of soluble factors in vitreous fluids from patients.

(A) IL-6, (B) IL-8, (C) MCP-1, and (D) VEGF levels in vitreous fluid of control patients and patients with DME, PDR, BRVO, CRVO, and RRD. The ordinate showed the concentrations of soluble factors in the log scale, bars represent the mean value of each group. * P<0.05, N.S.: not significant.

[Figure ID: pone-0008158-g002]
doi: 10.1371/journal.pone.0008158.g002.
Figure 2  IL-6, IL-8 and MCP-1 were mutually increased in all examined vitreoretinal diseases.

As an example, Spearman's correlation analysis of DME are shown (n?=?92). In each disease, total of three combinations (IL-6/IL-8, IL-6/MCP-1, and IL-8/MCP-1) were created, and calculated p- and r-values which indicating the accuracy of correlation.

[Figure ID: pone-0008158-g003]
doi: 10.1371/journal.pone.0008158.g003.
Figure 3  Summary of correlation analysis.

The combination of two factors was calculated for each individual disease and listed in the ordinate.

[Figure ID: pone-0008158-g004]
doi: 10.1371/journal.pone.0008158.g004.
Figure 4  VEGF independently contribute to the pathogenic process of PDR and CRVO.

Spearman's correlation analysis between VEGF and IL-6/IL-8/MCP-1 in patients with PDR (n?=?147) or CRVO (n?=?13) are shown. In each disease, total of three combinations (VEGF/IL-6, VEGF/IL-8, and VEGF/MCP-1) were analyzed, and calculated p- and r-values which indicating the accuracy of correlation.

[Figure ID: pone-0008158-g005]
doi: 10.1371/journal.pone.0008158.g005.
Figure 5  Serum IL-6 and VEGF concentrations are not significantly related with vitreous concentrations.

Shown are comparison of (A) IL-6, and (B) VEGF levels in vitreous and in serum of patients with control (n?=?53), PDR (n?=?66) and CRVO (n?=?8). The ordinate showed the concentrations of soluble factors in the log scale, bars represent the mean value of each group. Bars represent the mean value of each group. * P<0.01, N.S.: not significant.

[Figure ID: pone-0008158-g006]
doi: 10.1371/journal.pone.0008158.g006.
Figure 6  Possible contribution of major four factors: IL-6, IL-8, MCP-1 and VEGF in vitreoretinal diseases.

A scheme illustrates the relations between the different mediators in samples from the different vitreoretinal diseases: IL-6, IL-8, and MCP-1 in the vitreous cavity can increase vascular permeability that causes DME, but an additional retinal ischemia led to increased VEGF production that play an important role in the progression of DME to PDR. At the same time, high VEGF levels may be initially produced by the sudden profound retinal injury, and then induced major three factors, frequently resulted in rubeosis iriditis.

[TableWrap ID: pone-0008158-t001] doi: 10.1371/journal.pone.0008158.t001.
Table 1  The bibliography of enrolled patients (age: mean?SD).
female male total
control n?=?57 (65.7?8.2) n?=?26 (67.8?6.8) n?=?83 (66.4?7.8)
DME n?=?46 (63.9?7.4) n?=?46 (62.4?9.7) n?=?92 (63.0?8.6) DME/PDR: p<0.0001?
PDR n?=?43 (56.3?13.6) n?=?104 (55.6?12.1) n?=?147 (55.8?12.5)
BRVO n?=?17 (70.0?10.6) n?=?13 (69.2?11.2) n?=?30 (69.7?10.7) BRVO/CRVO: p?=?0.5969?
CRVO n?=?7 (69.6?11.0) n?=?6 (74.0?11.1) n?=?13 (71.6?10.8)
RRD n?=?28 (62.3?12.0) n?=?35 (60.6?9.3) n?=?63 (61.4?10.5)
P value p?=?0.0003* p<0.0001* p<0.0001*

*Kruskal-Wallis test,

?Mann-Whitney U test.

[TableWrap ID: pone-0008158-t002] doi: 10.1371/journal.pone.0008158.t002.
Table 2  Concentrations of cytokines in the vitreous cavity.
IL-1? IL-2 IL-4 IL-5 IL-6 IL-10 IL-17 IFN-? TNF-?
Control <150 <60 <50 <30 12.1(<30?206.8) <50 <100 <50 <100
DME <150 <60 <50 <30 174(<30?1152) <50 <100 <50 <100
PDR <150 <60 <50 <30 330.1(<30?8630) <50 <100 <50 <100
BRVO <150 <60 <50 <30 65.6(<30?326) <50 <100 <50 <100
CRVO <150 <60 <50 <30 985.4(<30?11103) <50 <100 <50 <100
RRD <150 <60 <50 <30 701.6(<30?15381) <50 <100 <50 <100

Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.

[TableWrap ID: pone-0008158-t003] doi: 10.1371/journal.pone.0008158.t003.
Table 3  Concentrations of chemokines in the vitreous cavity.
IL-8 eotaxin MCP-1 MIP-1? MIP-1? RANTES
control 28.9(<30?1538) <50 100.8(<100?2146.9) <100 <100 <150
DME 258(<30?5522) <50 1590.1(<100?38394) <100 <100 <150
PDR 394.2(<30?11700) <50 1665(<100?31099.5) <100 <100 <150
BRVO 473.2(<30?7728) <50 439.1(<100?2895) <100 <100 <150
CRVO 1027(<30?6822) <50 2906(195?15045) <100 <100 <150
RRD 285.9(<30?4757) <50 3944(<100?35811) <100 <100 <150

Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.

[TableWrap ID: pone-0008158-t004] doi: 10.1371/journal.pone.0008158.t004.
Table 4  Concentrations of growth factors in the vitreous cavity.
control <150 111.0(<150?642.4) <150 <150 <150
DME <150 175.2(<150?1500.8) <150 <150 <150
PDR <150 545.7(<150?7900.0) <150 <150 <150
BRVO <150 167.4(<150?1977.0) <150 <150 <150
CRVO <150 1635.0(<150?11737) <150 <150 <150
RRD <150 77.4(<150?712) <150 <150 <150

Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.

[TableWrap ID: pone-0008158-t005] doi: 10.1371/journal.pone.0008158.t005.
Table 5  Concentrations of IL-6 and VEGF in the vitreous and serum.
vitreous IL-6 serum IL-6 vitreous VEGF serum VEGF
control 13.2(<30?237.1) 139.4(<47.0?1070) 139.6(<150?642.4) 47.8(<156.5?459.4)
PDR 463.3(<30?8630) 97.0(<47.0?875.3) 584(<150?6700) 53.1(<156.5?407.6)
CRVO 1502(<30?11104) 40.6(<47.0?254.0) 2168(<150?11737) 23.8(<156.5?214.4)

Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.

Article Categories:
  • Research Article
Article Categories:
  • Biotechnology
  • Immunology
  • Ophthalmology

Previous Document:  Distinct Roles for ROCK1 and ROCK2 in the Regulation of Keratinocyte Differentiation.
Next Document:  Regional gene expression of LOX-1, VCAM-1, and ICAM-1 in aorta of HIV-1 transgenic rats.